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In a search for more selective A1 adenosine receptor agonists, N'-[(R)-(-)-1-methyl-2-phenethyl]-1-deazaadenosine (1-deaza-R-PIA, 3a), N'-cyclopentyl-1-deazaadenosine (1-deazaCPA, 3b), .N6-cyclohexyl-l-deazaadenosine (1-deazaCHA, 
Sc), and the corresponding 2-chloro derivatives 2a-c were synthesized from 5,7-dichloro-3-ß-D-ribofuranosyl-3H-
imidazo[4,5-b]pyridine (1). On the other band, N-ethyl-1'-deoxy-1'-(1-deaza-6-amino-9H-purin-9-yl)-ß-D-ribo-
furanuronamide (1-deazaNECA, 10) was prepared from 7-nitro-3-ß-D-ribofuranosyl-3H-imidazo[4,5-b]pyridine (4), 
in an attempt to find a more selective A2 agonist. The activity of all deaza analogues at adenosine receptors has 
been determined in adenylate cyclase andin radioligand binding studies. 1-DeazaNECA (10) proved tobe a nonselective 
agonist at both subtypes of the adenosine receptor. lt is about 10-fold less active than NECA but clearly more active 
than the parent compound 1-deazaadenosine as an inhibitor of platelet aggregation and as a stimulator of cyclic 
AMP accumulation. The N6-substituted 1-deazaadenosines largely retain the A1 agonist activity of their parent 
compounds, but lose some of their A2 agonist activity. This results in A1-selective compounds, of which Nß-
cyclopentyl-2-chloro-1-deazaadenosine (1-deaza-2-Cl-CPA, 2b) was identified as the most selective agonist at A1 
adenosine receptors so far known. The activity of all1-deaza analogues confirms that the presence of the nitrogen 
atom at position 1 of the purine ring is not critical for A1 receptor mediated adenosine actions. 
Adenosine appears to mediate a wide variety of physi-
ological functions including vasodilatation, vasoconstriction 
in the kidney, cardiac depression, inhibition of lipolysis, 
inhibition of platelet aggregat1on, inhibition on lymphocyte 
functions, inhibition of insulin release and potentiation of 
glucagon release in the pancreas, inhibition of neurotran· 
smitter release from nerve endings, Stimulation of ster-
oidogenesis, and potentiation of histamine release from 
mast cells.1- 5 Many of its effects can be attributed to the 
action at receptors located on the cell surface. · Two classes 
of adenosine receptors that either inhibit (A1 or Ri) or 
stimulate (A2 or R8 ) the activity of adenylate cyclase have 
been identified both on the basis of pharmacological pro-
flies of sets of adenosine analogues and of the intracellular 
events coupled to receptor occupation.1 
This interaction of adenosine with the receptors is very 
specific and requires the presence of both the adenine and 
the ribose moieties. The most prominent determinants 
for adenosine actions seem to be its 6-amino group, even 
if monosubstituted, the ß-anomeric configuration of the 
ribose, and the ribofuranose C2' and C3' hydroxylic 
groups.6•7 
At A1 receptors the most active analogues are N6-sub-
stituted adenosines, whereas at A2 receptors the most ac· 
tive compounds are N-alkyladenosin-5'-uronamides. Two 
adenosine analogues, N6- [ (R)- (-) 1-methyl-2-phenethyl]-
adenosine (R-PIA) and ethyladenosin-5'-uronamide 
(NECA), have been developed as important reagents for 
identifying A1 and A2 receptors, respectively. NECA is not, 
however, A2 selective. 8 A1 receptors · exhibit a potency 
order R-PIA > NECA, whereas A2 receptors exhibit a 
reverse order. 1 
Recently, in order to investigate the role of the purine 
nitrogens, we have examined the effects of several deaza 
analogues of adenosine on rat brain membranes and on 
human platelets.9 It was found that 1-deazaadenosine, 
though less active than adenosine, displays the highest 
affinity for adenosine receptors whereas 3-deazaadenosine 
is very little active; 7-deaza- and 1,3-dideazaadenosine are 
inactive. 
In order to get further information about the factors 
governing the binding of the purine domain to adenosine 
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receptors and in an attempt to find more active and/ or 
more selective derivatives, we have synthesized and bio-
logically evaluated a series of 1-deaza analogues of R-PIA, 
CHA (N8-cyclohexyladenosine), and CPA (Ni-cyclo-
pentyladenosine) (2a-d and 3a-d). We report also the 
synthesis and the biological activity of the N-ethyl-1 '· 
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Table I. N8-Substituted 1-Deazaadenosines from Scheme I 
compd R X rectn time, h 
2a (R)-CH(CH3)CH2CaHs Cl 48 
2b c·C5H9 Cl 24 
2c c·CsHu Cl 24 
3a (R)·CH(CH3)CH2CaHö H 5 
3b c·C&He H 8 
3c c-C6H11 H 8 
chromat solvent 
CHC13-c-C6H12-MeOH (70:17:13) 
Ac0Et-Me0H-NH3 
(94:5:1) 
CHC13-Me0H-NH3 (85:14:1) 
CHC13-MeOH 
(90:10) 
AcOEt-MeOH 
(95:5) 
CHC13-MeOH-NH3 (80:19:1) 
yield,% 
70 
50 
50 
80 
70 
60 
mp," °C 
99-102 
166-168 
188-190 
162-165 
94-96 
134-137 
Cristalli et al. 
formulab 
C2oH23ClN40 4 
CtsH21ClN404 
C11H23ClN404 
"Uncorrected. bAll compounds had satisfactory C, H, N, microanalyses and were within 0.4% of theoretical value. All cornpounds 
exhibited 1H NMR spectra consistent with the assigned structures. 
Table II. Effects of 1-Deazaadenosine Analogues, NECA, CPA, and R-PIA on Adenylate Cyclase 
A1 receptor A2 receptor A1 selectivity, 
compd IC60, nM inhibn (rel)" EC60, nM stimul (rel)" EC~0/IC60 
1-deazaadenosine 6700 0.97 :C 0.05 18000 0.60 :C 0.04 2.7 
(4100-11000) (11000-28000) 
1-deaza-2-Cl-PIA (2a) 960 1.08 :C 0.09 3500 0.40 :C 0.13 3.6 
(380-2400) (2600-4 700) 
1-deazaPIA (3a) 630 1.16 :C 0.26 6600 0.32 :C 0.05 10.5 
(530-760) (4800-9000) 
1-deaza-2-Cl-CPA (2b) 360 1.07 :C 0.12 . 28000 0.43 :C 0.03 78 
(220-660) (20000-39000) 
1-deazaCPA (3b) 970 1.07 :C 019 26000 0.39 :C 0.02 27 
(610-1500) (20000-34000) 
1-deaza-2-Cl-CHA (2c) 2400 1.14 :C 0.21 4800 0.34 :C 0.09 2.0 
(2100-7000) (3200-7200) 
1-deazaCHA (3c) 1600 1.09 :C 0.12 20000 0.38 :C 0.02 12.4 
(1000-2500) (17000-23000) 
1-deazaNECA (10) 1500 1.04 :C 0.13 2800 0.57 :C 0.13 1.9 
(1200-1900) (2100-3900) 
R-PIA 40' 950 0.53 ::1: 0.06 24 
(22-72) (650-1400) 
CPA 58 0.99 ::1: 0.07 2200 0.51 :C 0.09 38 
(24-140) (1500-3200) 
NECA 200 0.93 ::1: 0.12 260 1.3 
(160-250) (190-360) 
"The maximal inhibition or stimulation of adenylate cyclase activity by the compounds are given relative to the reference compounds 
R-PIA for the A1 receptor and NECA for the A2 receptor. The inhibition by R-PIA was 53 ::1: 10% and the stimulation by NECA 250 ::!: 30% (means and SEMs of nine independent experiments). Values are mearis and SEMS or 95% confidence intervals of three independent 
determinations. 
deoxy-1' • ( 1-deaza-6-amino-9H -purin-9-yl)-ß-D· ri bofuran-
uronamide (10), the 1-deaza analogue of NECA, the most 
potent adenosine analogue at A2 receptors so far known.1 
Chemistry. The synthetic pathways for the preparation 
of compounds 2a-c and 3a-c listed in Table I, are shown 
in Scheme I. Reaction of 5, 7 -dichloro·3·ß-n-ribo-
furanosyl-3H-imidazo(4,5-b]pyridine (1)9 with the appro-
priate amine gave the N6-substituted 2-chloro-1-deaza-
adenosines 2a-c. Catalytic hydrogenolysis of the chlorine 
atom in '2a-c with 10% Pd/C in ethanol and 2 N NaOH 
afforded the corresponding derivatives 3a-c. 
The synihesis of N-ethyl-1'-deoxy-1'·(1-deaza-6-amino-
9H-purin-9-yl)-ß-D-ribofuranuronamide (1-deazaNECA, 
10) was accomplished by the method outlined in Scheme 
11. Protection of 7-nitro-3-ß·D·ribofuranosyl-3H-
imidazo[4,5-b]pyridine (4)10 gave the 2',3'·0-isopropylidene 
derivative 5, which was oxidized with pyridinium di-
chromate (PDC) to yield the uronic acid 6. 
The 2',3'·0-protected N-ethylribofuranuronamide de· 
rivative 7 was formed by first converting the acid 6 to its 
acid chloride with SOC12 under mild conditions followed 
by reaction of the acid chloride with dry ethylamine in 
(10) Cristalli, G.; Franchetti, P.; Grifantini, M.; Vittori, S.; Bordoni, 
T.; Geroni, C. J. Med. Chem. 1987, 30, 1686. 
chloroform at 0 °C. Deblocking of the isopropylidene 
protective group by 1 N HCl at 45 °C gave N-ethyl-1'-
deoxy-1'-(1-deaza-6-nitro-9H-purin-9-yl}-ß-n-ribofuran-
uronamide (8) in 85% yield. 
Attempts tO convert 8 directly to 1-deazaNECA (10) by 
means of several reduction systems (H2 and Pd/C or Pt 
or Raney nickel, also in the presence of acids or hases, Zn 
and acids) were unsuccessful, resulting in the denitrated 
purine derivative.9. The structure of compound 9 was 
assigned by 1H NMR analysis. Its 1H NMR spectrum 
showed the presence of a doublet of doubletat ö 7.40 (H-1), 
two doublets at 8.22 (H-6) and 8.45 (H-2), respectively, and 
a singlet at 8. 78 (H-8). 
This lability of the nitro group prompted us to attempt 
its substitution with hydrazine hydrate at reflux and then 
reduction of the crude reaction mixture with Raney nickel. 
The structure of 1-deazaNECA (10) thus obtained was 
clearly confirmed by 1H NMR and eiemental analyses. 
Biological Evaluation. The activity of the deaza-
adenosine analogues was determined in adenylate cyclase 
studies with rat fat cell membranes as an A1 receptor se-
lective model and human platelet membranes as an A2 
receptor selective model. The results are given in Table 
II. The extent of maximal inhibition by all compounds 
is comparable tothat of the most widely used A1 receptor 
1-Deaza Analogues of Adenosine Derivatives 
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agonist R-PIA, but the IC50 values were on the whole 
somewhat higher for the 1-deaza compounds compared to 
their nondeaza counterparts. 
In contrast, maximal stimulation of adenylate cyclase 
activity of human platelet membranes as stimulated by the 
deaza compounds was somewhat lower than by R-PIA 
(about 130%), but clearly less than by NECA (250%). 
Thus, the deaza compounds may be regarded as partial 
agonists at the A2 receptor. Again, the EC50 values of the 
deaza analogues were always higher than those of their 
parent compounds. · 
All compounds showed some degree of A1 selectivity on 
the basis of a comparison of IC60 and EC60 values. In the 
case of 1-deazaPIA (3a) and 1-deazaCHA (3c) the 2-Cl-
substituted derivative.s had a lower A1 selectivity than the 
unsubstituted compounds (2a and 2c). The contrary was 
true for 1-deazaCPA (3b): here the 2-Cl-substitution re-
sulted in an· increase of the A1 selectivity,· and in fact 
.Nß-cyclopentyl-2-chloro-1-deazaadenosine (1-deaza-2-Cl-
CPA, 2b) had a more than twofold higher selectivity than 
.Nß-cyelopentyladenosinß (OPA), which so far has been the 
most selective agon~st at A1 recept~r.11 · 
(11} Moos, W. H.; Szotek, D. S.; Bruns, R. F. J. Med. Chem. 1985, 
28, 1383. 
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Table 111. Effects of 1-Deazaadenosine Analogues, NECA, CPA, 
and R-PIA on Radioligand Binding to Adenosine Receptors 
Khanm Al selectivity, 
Al Az Ki(A2)/ 
compd receptor receptor Ki(At} 
1-deazaadenosine 115 2900 25 
(91-144} (2400-3500) 
1-deaza-2-Cl-PIA (2a} 18 3700 210 
(15-23) (350Q-4000) 
1-deazaPIA (3a) 7.7 4900 640 
(7.3-8.1} (3300-7300) 
1-deaza-2-Cl-CPA (2b} 1.6 13200 8200 
(1.1-2.5} (1090o-15900} 
1-deazaCPA (3b} 7.5 17600 2300 
(5.7-9.7) (12300-25000} 
1-deaza-2-CI-CHA (2c} 47 8200 170 
(42-54} (510Q-13200} 
1-deazaCHA (3c} 16 6800 420 
(11-24) (410Q-11200) 
1-deazaNECA (10} 51 580 12 
(41~3) (540-630) 
R-PIA 1.3 730 560 
(1.1-2.4} (69Q-770) 
CPA 0.8 2000 2500 
(0.6-1.0} (1400-2900} 
NECA 8.2 22 2.7 
(6.2-10.9) (20-25} 
a K1 values were calculated from competition for [3H]PIA bind-
ing to rat brain membranes (A1 receptor} and for [3H]NECA 
binding to rat striatal membranes in the presence of 50 nM CPA 
(A2 receptor}. Data represent means and 95% confidence intervals 
of three independent determinations. 
In addition, the affinity for adenosine receptors was 
examined in radioligand binding studies. All compounds 
competed for the binding of [3H]PIA to A1 receptors with 
Hili factors of about 1. With the exception of NECA itself, 
all compounds also competed for the binding of [3H]NECA 
to bovine striatal membranes with Hili factors of about 
1, and the competition curves were adequately fitted, as-
suming a one-site model; this suggests that these com-
pounds did not compete for the low-affinity nonreceptor 
binding of [3H]NECA.8 In analogy to the data of Bruns 
et al.,8 the high affinity component of the competition of 
NECA for [3H]NECA bindingwas regarded as A2 receptor 
binding. The Ki values of the competition are given in 
Table III. The same order of potency and selectivity was 
öbtained with bovine striatal membranes as the source of 
A2 receptors, although the affmities for the bovine receptor 
were somewhat higher.12 This suggests that at least for 
the. ~ompounds studied in this report there are no major 
differences betwee~ the bovine and the rat striatal A2 
receptor. 
In agreement with other studies, 11 the binding experi-
ments suggest a much higher A1 selectivi"ty of the com-
pounds than adenylate cyclase experiments. This is due 
to the higher affinity of the agonists for A1 receptors in 
binding studies, which may reflect the formation of the 
high affinity state in the absence of guanine nucleotides.13 
Differe'nces between the A2 receptors of human platelets 
and rat and bovine striatum may also be the reason for this 
discrepancy. However, the order of selectivity remains 
essentially the same: 1-deaza-2-Cl-CPA (2b) has a three-
fold hjgher selectivity than CPA, although the value of 
2500 for CPA is hjgher than the value of 783 originally 
(12) Grifantini, M.; Cristalli, G.; Franchetti, P.; Vittori, S.; Klotz, 
K. N.; Lohse, M. J. Actualites de Chimie Therapeutique 158 
Serie, Societe de Chimie Theiapeutique ed Chateney-Molabzy, 
1988; p 217. 
(13) Lohse, M. J.; Lenschow, V.; Schwabe, U. Mol. Pharmacol. 
1984, 26, 1. 
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Table IV. Activity of 1-DeazaNECA as an Inhibitor of Platelet 
Aggregation Induced by ADP4 
1-deazaNECA 5.96 (5.18-6.85) 
1-deazaadenosine 65.5 (49.5-86.7) 
NECA 0.60 (0.52-ü.70) 
adenosine 5.94 (3.25-10.85) 
4 ADP concentration was 7 ~M. b Concentration that inhibits 
platelet aggregation by 50%. Data represent means and 95% 
confidence intervals of three independent determinations. 
reported by Moss et al.11 Several deaza compounds have 
a higher A1 selectivity than R-PIA in the binding experi-
ments. 
1-DeazaNECA (10) has been alsostudiedas an inhibitor 
of platelet aggregation induced by ADP. The results, given 
in Table IV, showed that 1-deazaNECA (10) is about 10-
fold more active than 1-deazaadenosine with an IC50 Value 
of 5.96 ,uM. NECA is also 10-fold more active than 
adenosine.14 This finding confirms that in the series of 
1-deazaadenosine derivatives the presence of a 5'-[(ethy-
lamino)carbonyl] group increases the affinity for A2 re-
ceptors. 
In conclusion, 1-deazaNECA (10) can be regarded as 
nonselective agonist at both subtypes of the adenosine 
receptor, whereas N6-substituted 1-deazaadenosines largely 
retain the A1 agonist activity of their parent compounds, 
but lose some of their A2 agonist activity. This results in 
A1·selective compounds, ofwhich 1-deaza-2-Cl-CPA (2b) 
wa.S identified as the most selective agonist at A1 adenosine 
receptors so far known. In addition, the activity of all 
1-deaza analogues points out once more that the presence 
of the nitrogen atom at position 1 of the purine ring is not 
critical for the adenosine actions.15 
Experimental Section 
Chemistry. Melting points were determined with a Büchi 
apparatus and are uncorrected. 1H NMR spectra were obtained 
with a Varian EM-390 90-MHz spectrometer, with tetra-
methylsilane as an internal standard. IR spectra were recorded 
on a Perkin-Eimer Model 297 spectrophotometer. TLC were 
carried out on precoated TLC plates with silica gel 60 F-254 
(Merck). For column chromatography, silica gel (Merck) was used. 
Microanalytical results are indicated by atomic symbols and are 
within :1:0.4% of theoretical values. 
Preparation of N'-Substituted 2-Chloro-1-deazaadenosines 
(2a-c). To a solution of 5,7-dichloro-3-ß-D-ribofuranosyl-3H-
imidazo[4,5-b]pyridine9 (1.1 mmol) in ethanolwas added the 
appropriate amine (4 mmol). The reaction mixturewas heated 
at 135 °C in a sealed tube (Table 1). The solvent was removed 
in vacuo, and the residue was chromatographed on a silica gel 
column, eluting with a suitable mixture of solvents (Table I) to 
give 2a-c as chromatographically pure solids. All of the spectral 
data for the compounds were compatible with the structures. 
Preparation of Nli-Substituted 1-Deazaadenosines (3a-c). 
To a solution of 2a-c (1 mmol) in 80 mL of ethanol and 2 mL 
of 2 N NaOH was added 0.3 g of 10% Pd/C, and the mixturewas 
shaken with hydrogen at 50 psi for the time reported in Table 
I. The catalyst was removed, and the filtrate was concentrated 
to dryness. The residue was chromatographed on a silica gel 
column, eluting with the solvent mixtures reported in Table I to 
give 3a-c a.s pure solids. All of the spectra data for the compounds 
were compatible with the structures. 
1-Deaza-6-nitro,9-(2' ,3'- 0 -isopropylidene-ß-D·ribo-
furanosyl)-9H -purine (5). To a solution of 5.4 g (18 mmol) of 
7-nitro-3-ß-o-ribofuranosyl-3H-imidazo[4,5-bJpyridine (4)10 in 400 
mL of acetone was added 34.5 g of p-toluenesulfonic acid. The 
(14) Cusack, N. J.; Hourani, S. M. 0. Br. J. Phar",nacol. 1981, 72, 
443. 
(15) Antonini, 1.; Cristalli, G.; Franchetti, P.; Grifantini, M.; Mar-
telli, S.; Petrelli, F. J. Pharm. Sei. 1984, 73, 366. 
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reaction mixture was stirred at room temperature for 1 h and then, 
after the addition of 54 g of NaHC03, stirred again for 3 h. The 
solid was removed and washed two times with EtOAc, and the 
filtratewas concentrated to dryness. The residue was chroma-
tographed on a silica gel column, eluting with EtOAc to give 4.34 
g (71 %) of 5 as a solid: rnp 109-112 °C; 1H NMR (Me2SO-d6) 
~ 1.34 and 1.56 (s, 6 H, C(CH3) 2), 3.58 (d, J = 5 Hz, 2 H, CH2-5'), 
4.32 (m, 1 H, H-4'), 4.59 (s, 1 H, OH), 5.02 (m, 1 H, H-3'), 5.43 
(m, 1 H, H-2'), 6.39 (d, J = 2.5 Hz, 1 H, H-1'), 8.05 (d, J 2,1 = 7 
Hz, 1 H, H-2), 8.74 (d, J 1,2 =7Hz, 1 H, H-1), 9.03 (s, 1 H, H-8). 
Anal. (C14H16N40 6) C, H, N. 
1'-Deoxy-1'-(l-deaza-6-nitro-9H-purin-9-yl)-2',3'-0-iso-
propylidene-ß-D-ribofuranuronic Acid (6). To a solution of 
4 g (11.9 mmol) of 5 in 30 mL of dry N,N-dimethylformamide 
was added 13.4 g of pyridinium dichromate (PDC), and the 
mixture was set aside in the dark at room temperature for 30 h. 
The reaction mixture was extracted several times with EtOAc, 
and the organic layers were collected, dried (Na2S04), and 
evaporated. The residue was triturated with a mixture of 
CHC13-MeOH (95:5), and the resulting solid was filtered and 
washed with EtOAc to give 1.67 g ( 40%) of 6 as a white solid: mp 
206-208 °C dec; IR Vmax 1728 (COOH); 1H NMR (Me2SO-d6) ~ 
1.41 and 1.58 (s, 3 H, C(CH3) 2), 4.81 (s, 1 H, H-4'), 5.61 (s, 2 H, 
H-3' and H-2'), 6.60 (s, 1 H, H-1'), 8.04 (d, J2,1 = 5.3 Hz, 1 H, H-2), 
8.65 (d, J 1,2 = 5.3 Hz, 1 H, H-1), 8.98 (s, 1 H, H-8), 13.00 (s, 1 H, 
COOH). Anal. (C14H14N40 7) C, H, N. 
N -Ethyl-1'-deoxy-l'-(l-deaza-6-nitro-9H -purin-9-yl)-
2',3'-0-isopropylidene-ß-o-ribofuranuronamide {7). A solu-
tion of 1 g (2.85 mmol) of 6 in 4.5 mL of dry DMF was added 
dropwise to 9 mL of ice-cooled SOCI2• The mixture was stirred 
at 0 °C for 30 min and then allowed to warm to room temperature 
and stirred for 2 h. After evaporation in vacuo at room tem-
perature (oil pump), the crude acidchloridewas dissolved in 12 
mL of dry CHC13, and the solution was added dropwise to an 
ice-cooled mixture of 2 mL of dry ethylamine in 23 mL of dry 
CHC13• After 10 min, the reaction mixture was carefully con-
centrated in vacuo and the residue was dissolved in water and 
extracted several times with CHC13• The organic phase was dried 
(Na2S04) and evaporated, and the residue was chromatographed 
on a silica gel column. Elution with Et0Ac-c-C6H 12 (50:50) gave 
500 mg (46%) of 7 as a solid: mp 65-67 °C; IR Vmax 1665 (C=O, 
amide); 1H NMR (Me280-d6) o 0.55 (t, 3 H, CH2CH3) 1.38 and 
1.58 (s, 3 H, C(CH3h, 2.76 (m, 2 H, CH2CH3), 4.61 (s, 1 H, H-4'), 
5.52 (s, 2 H, H-3' and H-2'), 6.55 (s, 1 H, H-1'), 7.48 (d, J 2,1 = 5.5 
Hz, 2 H, H-2 and NH), 8.31 (d, J 1,2 = 5.5 Hz, 1 H, H-1), 8.74 (s, 
1 H, H-8). Anal. (C16H19N50 6) C, H, N. 
N-Ethyl-1'-deoxy-1'-(l-deaza-6-nitro-9H-purin-9-yl)-ß-D-
ribofuranuronamide (8). A solution of 400 mg (1.06 mmol) of 
7 in 10 mL of 1 N HCl was heated at 45 oc for 1 h. The reaction 
mixturewas neutralized with solid NaHC03 and then extracted 
several times with EtOAc. The combined extracts were dried 
(Na2S04) and concentrated in vacuo to a residue, which was 
chromatographed on a silica gel column. Elution with CHC13-
Me0H (92:8) yielded 300 mg (85%) of 8 as a solid: mp 103-106 
°C; 1H NMR (Me2SO-ds) ~ 1.20 (t, 3 H, CH2CH3), 3.43 (m, 2 H, 
CH2CH3), 4.40 (m, 2 H, H-3' and H-4'), 4.81 (m, 1 H, H-2'), 6.30 (d, J = 8Hz, 1 H, H-1'), 7.65 (d, J 2,1 = 5.5 H, H-2), 8.50 (d, J1.2 
= 5.5 Hz, 2 H, H-1 and NH), 9.02 (s, 1 H, H-8). Anal. (C13-
H15N506) C, H, N. 
N -Ethyl-1'-deoxy-1'-(1-deaza-9H -purin-9-yl)-ß-D-ribo-
furanuronamide (9). To a solution of 240 mg (1.71 mmol) of 
8 in 100 mL of methanolwas added 150 mg of 10% PdjC and 
1 mL of NaOH, and the mixturewas shaken with hydrogen at 
20 psi for 4 h. The catalyst was removed by filtration, the filtrate 
was evaporated to dryness, and the residue was chromatographed 
on a silica gel column. Elution with CH2Cl2-c-C6H12-EtOH 
(50:25:25) gave 145 mg (70%) of 9 as a solid: mp 130-133 °C; 
1H NMR (Me2SO-d6) ~ 1.09 (t, 3 H, CH2CH3), 3.25 (m, 2 H, 
CH2CH3), 4.21 (m, 1 H, H-3'), 4.34 (m, 1 H, H-4'), 4.74 (m, 1 H, 
H-2'), 6.14 (d, 1 H, J =7Hz, H-1'), 7.40 (dd, 1 H, H-1), 8.22 (d, 
J =7Hz, 1 H, H-6), 8.45 (d, J = 4.5 Hz, 1 H, H-2), 8.67 (m, 1 
H, NH), 8.78 (s, 1 H, H-8). Anal. (C13H 16N40 4) C, H, N. 
N-Ethyl-l'-deoxy-l'-(1-deaza-6-amino-9H-purin-9-yl)-ß-
D-ribofuranuronamide (l·DeazaNECA 10). A mixture of 240 
mg (0.71 mmol) of 8 and 10 mL of 85% hydrazinehydratewas 
refluxed for 1.5 h under nitrogen atmosphere. After the reaction 
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mixture was evaporated to dryness, 40 rnL of oxygen-free water 
and 2 g of Raney nickel catalyst was added to the residue, and 
the mixture was refluxed for 1.5 h. The catalyst was removed 
by filtration and evaporated in vacuo to a residue, which was 
chromatographed on a silica gel column. Elution with CHC13-
Me0H-NH3 (80:19:1) gave 110 mg (50%) of 10 as a,pure solid: 
mp 188-190 °C; IR vmax 1660 (C=O, amide); 1H NMR (Me2SO-de) 
6 1.10 (t, 3 H, CH2CH:J, 3.23 (m, 2 H, CH2CH:J, 4.12 (d, 1 H, H-3'), 
4.32 (s, 1 H, H-4'), 4.71 (m, 1 H, H-2'), 5.98 (d, J = 8.5 Hz, 1 H, 
H-1'), 6.48 (d, J1,2 = 5.5 Hz, 1 H, H-1), 6.60 (s, 2 H, NH2), 7.91 
(d, J 2,1 = 5.5 Hz, 1 H, H-2), 8.30 (s, 1 H, H-8), 9.44 (m, 1 H, NH). 
Anal. (C13H 17N50 4) C, H, N. 
Biological Studies. Membrane Preparation. Mernbranes 
frorn rat brain, rat striatum, and bovine striatum were prepared 
as described.13 Rat striatum was dissected according to Glowinski 
and lversen.16 Human platelet mernbranes were prepared by the 
method of Hoffman et a1.17 Ra:t fat cells were isolated as described 
by Honnor et al.,18 and their rnembranes were prepared according 
to McKeel and Jarett.19 
Adenylate Cyclase Assay. The activity of adenylate cyclase 
of the respective membranes was determined as previously de-
scribed. 20 · 
Radioligand Binding Assays. The binding of [3H]PIA to 
A1 adenosine receptors of rat brain mernbranes was measured at 
37 °C in the presence of adenosine deaminase as described.13 The 
binding of [3H]·5'-N-ethylamino)carbonyl]adenosine ([3H]NECA) 
to the A2 aenosine receptors of rat and bovine striatal membranes 
(16) Glowinski, J.; Iversen, L. L. J. Neurochem. 1966, 13, 655. 
(17) Hoffman, B. B.; Michel, T.; Brenneman, T. B.; Lefkowitz, R. 
J. Endocrinol. 1982, 110, 926. 
(18) Honnor, R. C.; Dhillon, G. S.; Londos, C. J. Biol. Chem. 1985, 
260, 15122. 
(19) McKeel, D. W.; Jarett, L. J. Gell. Biol. 1970, 44, 417. 
(20) Klotz, K. N.; Cristalli, G.; Grifantini, M.; Vittori, S.; Lohse, M. 
J. J. Biol. Chem. 1985, 260, 14659. 
was measured at 37 °C according to Bruns et al.,11 with the 
following modifications: the incubation volume was reduced to 
250 ~JL containing 100 ~ of protein; the A1 receptor was saturated 
with 50 nM cyclopentyladenosine. 
Data Analysis. Goncentration-response curves containing 
at least eight different concentrations in duplicate were fitted by 
nonlinear regression to the Hill equation as described.21 Binding 
data were analyzed by the curve-fitting program SCTFIT.22 With 
this program, the simplest model (one site) was considered tobe 
valid unless fitting with a more complex model resulted in a 
significantly better fit (p < 0.01, F test). 
Platelet Aggregation Assay. Inhibition of platelet aggre· 
gation induced by ADP was determined as previously described.15 
IC50 values for each inhibitor were estimated from graphical plots 
of present inhibition vs log molar concentration (at least three 
to five different concentrations) and were defined as the con-
centrations that produce 50% inhibition of the aggregatory re-
sponse to ADP. Data represent rneans and 95% confidence 
intervals of three independent deterrninations. 
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In this paper, we report on the synthesis and biological activity of a nurnber of N-alkylated spermine compounds. 
The dialkylspermines .Nl,.Nl2-dimethylspermine (DMSPM-2), Nl,.Nl2-diethylspermine (DESPM-3), and Nl,N12-
dipropylsperrnine (DPSPM-4) are all shown to inhibit the growth of L1210 cells in culture with IC60 values of less 
than 1 ~JM at 96 h. Furthermore, DESPM-3 is shown tobe similarly active against Daudi and HL-60 cells in culture. 
A structure-activity relationship is shown to exist between the position at which sperrnine is alkylated and its 
antiproliferative properties. The activity of 10 ~JM DESPM-3 against L1210 cells was shown tobe cytostatic, with 
greater than 90% cell viability by trypan blue exclusion, even after a 144-h exposure. When L1210 cells were treated 
with 10 ~JM DESPM-3 over a 144-h period, their size and rnitochondrial DNA content were gradually but substantially 
diminished. However, flow cytornetric rneasurements ofthe nuclear DNA content ofthese treated cells at 96 h indicated 
only slightly reduced Sand G2 populations and significant changes only after 144 h. A cloning assay performed 
on the· cells after 96 h of exposure to this drug (10 ~JM) indicated that the cells were not growing. Finally, when 
male DBA/2 mice, inoculated with L1210 leukemia cells, were treated with DESPM-3, their life spanwas increased 
in excess of 200% relative to untreated controls. Moreover, many long-terrn survivors were apparently turnor free 
at the end of the experiment (60 days). 
The role of polyamines in proliferative processes has 
received considerable attention in recent years.1- 5 In fact, 
interruption of the polyamine metabolic network has been 
at least partially successful in controlling the growth of 
cancer cells.6•7 The antineoplastic drugs, a-(difluoro-
methyl)ornithine (DFMO) and methylglyoxal bis(gua· 
t Department of Medicinal Chemistry. 
~ Department of Pharrnacology. 
nylhydrazone) (MGBG), are both potent inhibitors of en· 
zymes that are critical to polyamine biosynthesis. DFMO 
(1) Heby, 0. Di{ferentation 1981, 19, 1-20. 
(2) Tabor, C. W.; Tabor, H. Annu. Reu. Biochem. 1984, 53, 
749-790. 
(3) Bachrach, U.; Kaye, A.; Chayen, R., Eds. Aduances in Poly-
amine Research; Raven: New York, 1983; Vol. 4, p 808. 
(4) Janne, J.; Poso, H.; Raine A. Biochim, Biophys. Acta 1978,473, 
241-293. 
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